Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M. Kruit WH, et al. Among authors: van baren n, van der bruggen p, van ojik hh. Int J Cancer. 2005 Nov 20;117(4):596-604. doi: 10.1002/ijc.21264. Int J Cancer. 2005. PMID: 15945101 Free article. Clinical Trial.
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.
Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Liénard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jäger E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. Marchand M, et al. Among authors: van baren n, van der bruggen p. Int J Cancer. 1999 Jan 18;80(2):219-30. doi: 10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s. Int J Cancer. 1999. PMID: 9935203 Free article. Clinical Trial.
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T. van Baren N, et al. Among authors: van der bruggen p. J Clin Oncol. 2005 Dec 10;23(35):9008-21. doi: 10.1200/JCO.2005.08.375. Epub 2005 Aug 1. J Clin Oncol. 2005. PMID: 16061912 Clinical Trial.
Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.
Carrasco J, Van Pel A, Neyns B, Lethé B, Brasseur F, Renkvist N, van der Bruggen P, van Baren N, Paulus R, Thielemans K, Boon T, Godelaine D. Carrasco J, et al. Among authors: van pel a, van baren n, van der bruggen p. J Immunol. 2008 Mar 1;180(5):3585-93. doi: 10.4049/jimmunol.180.5.3585. J Immunol. 2008. PMID: 18292586 Clinical Trial.
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.
Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G. Marchand M, et al. Among authors: van baren n. Eur J Cancer. 2003 Jan;39(1):70-7. doi: 10.1016/s0959-8049(02)00479-3. Eur J Cancer. 2003. PMID: 12504661 Clinical Trial.
Peptide-based cancer vaccines.
Machiels JP, van Baren N, Marchand M. Machiels JP, et al. Among authors: van baren n. Semin Oncol. 2002 Oct;29(5):494-502. doi: 10.1053/sonc.2002.35244. Semin Oncol. 2002. PMID: 12407514 Review.
58 results